AstraZeneca invests SEK 30 million in obesity research at KI
Article excerpt
Highlighted: the sentence this signal was extracted from
AstraZeneca is investing just over SEK 30 million in four research projects in collaboration with Karolinska Institutet and Karolinska University Hospital. The initiative will run over the next five years and covers research into obesity, as well as kidney and liver diseases. The aim is to further strengthen Sweden's position as an international leader in life sciences. Karolinska Institutet, Karolinska University Hospital and AstraZeneca have an established, long-term partnership aimed at accelerating research and development in precision medicine in Sweden. AstraZeneca is now investing just over 30 million kronor to accelerate research into cardiometabolic and renal diseases. "Research of high scientific quality is crucial if we are to better understand complex diseases and develop the treatments of the future," says KI President Annika Östman Wernerson. "By bringing together academia, healthcare and industry, we are creating a strong environment for groundbreaking translational research." This expanded collaboration aims to yield innovative discoveries in several areas that can improve patients' health. One such area is obesity, and the obesity project represents a new field of research within the collaboration. By studying, amongst other things, the biological functions and significance of adipose tissue, the research aims to contribute to a deeper understanding of...
Keep reading with a free account
The rest of this article, and every signal for AstraZeneca, is in your free account.
